Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.47 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892939 | 0.91 | GCK (0.47) | GCKPTGS2MMP1MMP13 | |
| SCHEMBL1107301 | 0.87 | GCK (0.48) | GCKPTGS2ADAMTS4 | |
| SCHEMBL1107719 | 0.84 | MEN1 (0.58) | GCKPTGS2MEN1KMT2A | |
| SCHEMBL2667439 | 0.80 | GCK (0.54) | GCK | |
| SCHEMBL1107611 | 0.79 | MEN1 (0.52) | GCKPTGS2MEN1KMT2A | |
| SCHEMBL1528286 | 0.78 | GCK (0.48) | GCKMEN1KMT2A | |
| SCHEMBL505405 | 0.77 | IP6K1 (0.60) | IP6K1IP6K3IP6K2PTGS2PPARG | |
| SCHEMBL30362588 | 0.77 | IP6K1 (0.60) | IP6K1IP6K3IP6K2PTGS2PPARG | |
| SCHEMBL1140769 | 0.77 | MEN1 (0.50) | GCKPTGS2MEN1KMT2A | |
| SCHEMBL2654925 | 0.77 | MEN1 (0.49) | GCKPTGS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059522-B1 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8222285-B2 | 1,3-dihydroxy substituted phenylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222285-B2 | 1,3-dihydroxy substituted phenylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| WO-2008154563-A1 | 1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885IP6K1 15/4885IP6K3 19/4885 |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | GCKR, GCK, NR4A3 | GCK 2/4885IP6K1 305/4885IP6K3 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.